A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer

Jeremy Foote,Tyler E Mattox,Adam B Keeton,Xi Chen,Forrest T Smith,Kristy L Berry,Thomas W Holmes,Junwei Wang,Chung-Hui Wang,Antonio B Ward,Amit K Mitra,Veronica R Alcantara,Cherlene Hardy,Karianne G Fleten,Kjersti Flatmark,Karina J Yoon,Sujith Sarvesh,Ganji P Nagaraju,Dhana Sekhar Reddy Bandi,Yulia Maxuitenko,Jacob Valiyaveettil,Julienne L Carstens,Donald J Buchsbaum,Jennifer Yang,Gang Zhou,Elmar Nurmmedov,Ivan Babic,Vadim Gaponenko,Hazem Abdelkarim,Michael R Boyd,Gregory S Gorman,Upender Manne,Sejong Bae,Bassel F El-Rayes,Gary A Piazza

DOI: https://doi.org/10.1101/2023.05.17.541233

2024-10-07

Abstract:Here, we describe a novel pan-RAS inhibitor, ADT-007, that potently inhibited the growth of RAS mutant cancer cells irrespective of the RAS mutation or isozyme. RASWT cancer cells with GTP-activated RAS from upstream mutations were equally sensitive. Conversely, RASWT cancer cells harboring downstream BRAF mutations and normal cells were essentially insensitive to ADT-007. Sensitivity of cancer cells to ADT-007 required activated RAS and dependence on RAS for proliferation, while insensitivity was attributed to metabolic deactivation by UDP-glucuronosyltransferases expressed in RASWT and normal cells but repressed in RAS mutant cancer cells. ADT-007 binds nucleotide-free RAS to block GTP activation of effector interactions and MAPK/AKT signaling, resulting in mitotic arrest and apoptosis. ADT-007 displayed unique advantages over mutant-specific KRAS and pan-KRAS inhibitors, as well as other pan-RAS inhibitors that could impact in vivo antitumor efficacy by escaping compensatory mechanisms leading to resistance. Local administration of ADT-007 showed robust antitumor activity in syngeneic immune-competent and xenogeneic immune-deficient mouse models of colorectal and pancreatic cancer. The antitumor activity of ADT-007 was associated with the suppression of MAPK signaling and activation of innate and adaptive immunity in the tumor immune microenvironment. Oral administration of ADT-007 prodrug also inhibited tumor growth, supporting further development of this novel class of pan-RAS inhibitors for RAS-driven cancers.

Cancer Biology